Daxor Corporation (DXR) - Total Liabilities
Based on the latest financial reports, Daxor Corporation (DXR) has total liabilities worth $272.43K USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Daxor Corporation - Total Liabilities Trend (1985–2024)
This chart illustrates how Daxor Corporation's total liabilities have evolved over time, based on quarterly financial data. See DXR current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Daxor Corporation Competitors by Total Liabilities
The table below lists competitors of Daxor Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Electra Battery Materials Corp
V:ELBM
|
Canada | CA$100.05 Million |
|
Nahar Industrial Enterprises Limited
NSE:NAHARINDUS
|
India | Rs6.90 Billion |
|
City Service SE
WAR:CTS
|
Poland | zł66.34 Million |
|
Petra Energy Bhd
KLSE:5133
|
Malaysia | RM525.43 Million |
|
Nam Liong Global Corp
TWO:5450
|
Taiwan | NT$1.72 Billion |
|
Aplisens SA
WAR:APN
|
Poland | zł12.46 Million |
|
Cineverse Corp.
NASDAQ:CNVS
|
USA | $30.83 Million |
|
Toung LoongTextile Mfg Co Ltd
TWO:4401
|
Taiwan | NT$2.82 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Daxor Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Daxor Corporation stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daxor Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daxor Corporation (1985–2024)
The table below shows the annual total liabilities of Daxor Corporation from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $840.30K | -2.15% |
| 2023-12-31 | $858.76K | -33.51% |
| 2022-12-31 | $1.29 Million | -66.27% |
| 2021-12-31 | $3.83 Million | +336.26% |
| 2020-12-31 | $877.69K | -38.85% |
| 2019-12-31 | $1.44 Million | -68.55% |
| 2018-12-31 | $4.56 Million | -17.81% |
| 2017-12-31 | $5.55 Million | +5.18% |
| 2016-12-31 | $5.28 Million | -18.34% |
| 2015-12-31 | $6.47 Million | -69.88% |
| 2014-12-31 | $21.47 Million | +2.10% |
| 2013-12-31 | $21.02 Million | -0.91% |
| 2012-12-31 | $21.22 Million | -57.15% |
| 2011-12-31 | $49.51 Million | +12.01% |
| 2010-12-31 | $44.20 Million | +60.37% |
| 2009-12-31 | $27.56 Million | -17.39% |
| 2008-12-31 | $33.36 Million | -29.97% |
| 2007-12-31 | $47.64 Million | +46.47% |
| 2006-12-31 | $32.53 Million | +56.23% |
| 2005-12-31 | $20.82 Million | +29.74% |
| 2004-12-31 | $16.05 Million | +35.05% |
| 2003-12-31 | $11.88 Million | +48.05% |
| 2002-12-31 | $8.03 Million | -2.25% |
| 2001-12-31 | $8.21 Million | -24.69% |
| 2000-12-31 | $10.90 Million | +66.04% |
| 1999-12-31 | $6.57 Million | -25.38% |
| 1998-12-31 | $8.80 Million | +4.76% |
| 1997-12-31 | $8.40 Million | +52.73% |
| 1996-12-31 | $5.50 Million | -1.79% |
| 1995-12-31 | $5.60 Million | +43.59% |
| 1994-12-31 | $3.90 Million | -17.02% |
| 1993-12-31 | $4.70 Million | -54.37% |
| 1992-12-31 | $10.30 Million | +1.98% |
| 1991-12-31 | $10.10 Million | -9.01% |
| 1990-12-31 | $11.10 Million | +42.31% |
| 1989-12-31 | $7.80 Million | -30.97% |
| 1988-12-31 | $11.30 Million | +44.87% |
| 1987-12-31 | $7.80 Million | +11.43% |
| 1986-12-31 | $7.00 Million | +52.17% |
| 1985-12-31 | $4.60 Million | -- |
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corpo… Read more